Swiss Patients Face Barriers to New Drugs Amid 'Organised Theft' of Discounts

A staggering CHF 655 million intended for Swiss patients is being siphoned off by the very institutions meant to provide care. While the pharmaceutical industry grants nearly CHF 743 million in annual discounts, a bombshell report from the Federal Audit Office (SFAO) reveals that only 12% of that value—a measly CHF 88 million—actually reaches the pockets of insured citizens. This systemic failure has ignited a firestorm in Bern, with Socialist Party MP Baptiste Hurni branding the practice as 'organised theft.' Under Swiss law, these savings must be passed on to health insurers and policyholders, yet hospitals, doctors, and pharmacists are accused of utilizing 'inventive accounting' to retain the lion's share. This financial leakage occurs while Swiss households grapple with relentless increases in health insurance premiums, creating a bitter contrast between institutional profit and public burden. The Federal Office of Public Health (FOPH) now faces intense scrutiny for its failure to oversee a supply chain that has become a black hole for consumer savings.

Swiss patients are being denied access to a staggering one-third of all newly developed, innovative medicines. Despite Switzerland's reputation as a global pharmaceutical hub, a new Interpharma report warns that the nation is suffering a 'serious threat' to equal access. In a direct comparison, Switzerland currently offers only half of the new therapies available to patients in Germany. Between January 2025 and June 2026, pharmaceutical giants opted not to submit seven out of 22 innovative medicines for inclusion on the list of specialties. For three other critical treatments, companies didn't even bother filing for authorization with Swissmedic. This isn't just a bureaucratic delay; it is a calculated retreat that leaves patients with life-altering conditions—from rare genetic mutations to aggressive cancers—waiting for treatments that may never arrive on Swiss soil. The decline in patient care is no longer a hypothetical risk; it is a present reality.

The 'most-favoured-nation' (MFN) clause in US drug policy is casting a long, dark shadow over Swiss hospitals. To protect their lucrative American profit margins, pharmaceutical companies are strategically withholding new drug launches in Switzerland. Because US regulations often tie domestic prices to international benchmarks, a lower price in Switzerland could trigger a mandatory price collapse in the United States. Consequently, Swiss patients have become collateral damage in a global pricing war. Interpharma notes that 10 new treatments were intentionally withheld from the Swiss market for the 2025–2026 period to avoid jeopardizing US revenue. This geopolitical chess game means that even the wealthiest nation in Europe cannot guarantee its citizens the latest medical breakthroughs. The Swiss pricing system is now fundamentally incompatible with international trends, forcing a choice between high costs or no access at all.